Available courses

Case Studies in HAE: Diagnosing, Treating, and Managing the Patient With Hereditary Angioedema

Program Introduction

Explore Hereditary Angioedema treatment, emphasizing individualized care, first-line therapeutic options and investigational agents in clinical development. 

Learning Objectives

  • Analyze Hereditary Angioedema’s (HAE) pathophysiology to explain its underlying mechanisms.
  • Evaluate the impact of HAE on affected individuals to appreciate the condition's severity and implications.
  • Compare and contrast different therapeutic options available for HAE to determine their effectiveness.
  • Investigate and predict developments in future therapies for HAE to understand the direction of medical research and potential innovations.

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Untangling the Complexity of Alzheimer Disease With Effective Diagnostic Tools and Novel Treatment Options

Program Introduction

New biomarker technology and advancements in treatment options can lead to earlier diagnosis of Alzheimer disease and initiation of appropriate disease modifying therapies.

Learning Objectives

  • Identify biomarkers used in the early identification of Alzheimer disease
  • Assess the efficacy and safety data of novel investigational therapies for the management of Alzheimer disease
  • Implement advancements in diagnostic and screening tools for early Alzheimer disease assessment

Available Credit

  • 1.25 AMA PRA Category 1 Credits
  • 1.25 Participation
A Tailored Approach to Diagnosis and Early Treatment in Patients with Duchenne Muscular Dystrophy: A Real-World View of Quality of Life

Program Introduction

A detailed, modern digest of key advances in the diagnosis, treatment, and management of patients with Duchenne muscular dystrophy.

Learning Objective

After completing this educational activity, you should be able to: 

  • Use expert-guided treatment strategies for patients with Duchenne muscular dystrophy. 

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Optimizing Mental Health for Women: Recognizing and Treating Mood Disorders Throughout the Lifespan

Program Introduction

Mood disorders throughout women's reproductive stages require comprehensive care to alleviate unnecessary suffering, comorbidities, and unwanted outcomes.

Learning Objectives

After completing this educational activity, you should be able to:

  • Appraise the influence of the reproductive stage on mood disorders and comorbid psychiatric conditions in women
  • Assess factors involved in the diagnoses of mood disorders in women and the differential diagnoses and common comorbidities
  • Summarize evidence-based approaches for diagnosing and treating mood disorders in women

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Timely Diagnosis of Alzheimer Disease

Program Introduction

Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field.

Learning Objectives

  • Facilitate prompt treatment initiation for patients who have early-stage AD
  • Discuss the potential use of current and emerging agents focused on reducing disease progression with patients and their care partners

Available Credit

  • 0.50 AMA PRA Category 1 Credit
  • 0.50 Participation
Therapeutic Advances for Epileptic Seizure Rescue

Program Introduction

Neurologists and other clinicians can improve care by identifying individuals who are susceptible to seizure clusters and educating them on rescue therapies and medications. 

Learning Objectives

After completing this educational activity, you should be able to: 

  • Educate patients who are at risk for seizure clusters about rescue medications and emergency plans 
  • Provide rescue treatment for seizure clusters that patients are inclined to use 

Available credit: 

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Staying Up to Date with Evolving Postpartum Depression Pathophysiology and Treatment Research

Program Introduction

Early diagnosis of PPD is critical for mother-infant outcomes, and new hypotheses in its pathophysiology has led to novel and emerging therapies that can improve these outcomes.

Learning Objectives

After completing this educational activity, you should be able to: 

  • Examine the impact of delayed diagnosis on outcomes in PPD and best practices for management 
  • Explore pathophysiological mechanisms related to the expression of PPD symptoms 
  • Review clinical trial safety, efficacy, and dosing for current and emerging therapeutics for PPD 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Seizure Clusters in the Real World: The Call to Arms

Program Introduction

Treatment standards for neurologists and other clinicians caring for patients with epilepsy with emphasis on understanding epilepsy epidemiology, SUDEP and ILAE Classification updates, and therapeutic strategies. 

Learning Objectives

After completing this educational activity, you should be able to: 

  • Educate patients who are at risk for seizure clusters about rescue medications and emergency plans 
  • Provide rescue treatment for seizure clusters that patients are inclined to use 

Available Credit

  • AMA PRA Category 1 Credits
  • 0.5 Participation
Reviewing Non-Dopaminergic Mechanisms for Positive and Negative Schizophrenia Symptom Management

Program Introduction

What is the future of schizophrenia treatment? An in-depth exploration of novel, non-dopaminergic therapies transforming the standard of care for patients with schizophrenia’s positive and negative symptoms. 

Learning Objectives

After completing this educational activity, you should be able to: 

  • Outline current medication classes used in the treatment of schizophrenia 
  • Articulate side effect development and negative symptom control challenges associated with standard-of-care antipsychotics 
  • Review the latest research describing the biologic rationale of novel non-dopaminergic pathways in schizophrenia 
  • Analyze emerging clinical trial data for non-dopamine-targeting schizophrenia therapies 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Patient-Specific Considerations, the GABA Pathway, and New Clinical Trial Data on Neuroactive Steroids in MDD and PPD

Program Introduction

Studies evaluating neuroactive steroid GABAA receptor positive allosteric modulators demonstrate promising results for the treatment of MDD and PPD. 

Learning Objectives

After completing this educational activity, you should be able to:

  • Highlight the inadequacies of suboptimal depression treatment related to adherence, adverse effects, persistent symptoms/lack of efficacy, polypharmacy, and treatment resistance
  • Outline the underlying neurobiology of major depression and postpartum depression, with a focus on the GABAergic system 
  • Review the clinical trial data for approved and investigational GABAergic neuroactive steroid treatments 

Available Credit

  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Facilitating Treatment Initiation in Early-Stage Alzheimer Disease

Program Introduction

Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.

Learning Objective

  • Facilitate prompt treatment initiation for patients who have early-stage AD

Available Credit

  • 0.50 AMA PRA Category 1 Credit
  • 0.50 Participation
Diagnosing and Treating Alzheimer Disease During the Early Stage

Program Introduction

Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.

Learning Objectives

After completing this educational activity, you should be able to:

  • Identify patients with early-stage Alzheimer disease
  • Facilitate prompt treatment initiation for patients who have early-stage Alzheimer disease
  • Discuss the potential use of current and emerging agents focused on reducing disease progression with patients and their care partners

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Comparing LAI and Oral Antipsychotic Options: Expert Discussions with Schizophrenia Case Reports

Program Introduction

LAI antipsychotics are often initiated late in adults with schizophrenia, despite evidence supporting early use. Experts discuss the barriers to initiating LAI treatment, as well as adherence, efficacy and safety data.

Learning Objectives

After completing this educational activity, you should be able to:

  • Examine data comparing the efficacy of LAIAs and oral medications.  
  • Analyze the clinical trial data and unique considerations of available LAIAs.  
  • Implement early integration of LAIA therapies in appropriate patients.  

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Cognitive Impairment in Huntington Disease

Program Introduction

An updated review of pathophysiology, emerging treatments, and supportive care strategies in the cognitive dimension of Huntington disease. 

Learning Objectives

After completing this educational activity, you should be able to: 

  • Review the multisystem nature of Huntington disease  
  • Explore the clinical phenomenology of mild cognitive impairment in Huntington disease, including its impact on executive functioning  
  • Identify the possible role of NMDA receptors in the pathogenesis and treatment of Huntington disease 
  • Examine the current and emerging treatment landscape for nonmotor aspects of Huntington disease 
  • Examine the impact of multidisciplinary management on HD 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Best Practices for Management of Mental Health in Women: Focusing on Mood Disorders Throughout the Lifespan

Program Introduction

Diagnosis and tailored treatment of menstrual cycle- and menopausal-related mood disorders are key factors in helping women live the lives they want to live.

Learning Objectives

  • Appraise the influence of the reproductive stage on mood disorders and comorbid psychiatric conditions in women.
  • Assess factors involved in the diagnoses of mood disorders in women and the differential diagnoses and common comorbidities.
  • Summarize evidence-based approaches for diagnosing and treating mood disorders in women.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Agitation in Bipolar Disorder and Schizophrenia: Emergency Department Considerations

Program Introduction

In treating agitation in bipolar disorder/schizophrenia in the emergency department, consider efficacy and safety of therapies as well as the safety of patient and staff. 

Learning Objectives

After completing this educational activity, you should be able to: 

  • Better understand the nature and burden of agitation in bipolar disorder (BP) and schizophrenia (SZ) as it presents in the emergency department (ED) setting 
  • Better understand best practice guidelines for effective management of agitation in the ED setting 
  • Learn about newly approved therapeutics on the market to treat agitation and evaluate the efficacy and safety of each 

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Tweetorial: Parkinson’s Disease Psychosis: Current Therapies for Patients with PDP

The content for this activity is available here on Twitter

Overview

Management for Parkinson's disease psychosis (PDP) includes evaluating triggers, non-Parkinson's drugs, Parkinson's drugs that may contribute to symptoms, behavioral interventions, and multidisciplinary collaboration between health providers.

Learning Objective

After completing this educational activity, you should be able to: 

  • Implement evidence-based current therapies for patients with Parkinson’s Disease Psychosis

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
Tweetorial: Analyzing Two Schizophrenia Case Reports

The content for this activity is available here on Twitter

Overview

Experts discuss appropriate treatment sequencing for patients with schizophrenia, including early use of LAIs and switching from an oral antipsychotic. 

Learning Objectives

After completing this educational activity, you should be able to: 

  • Examine data comparing the efficacy of LAIAs and oral medications.   
  • Analyze the clinical trial data and unique considerations of available LAIAs.   
  • Implement early integration of LAIA therapies in appropriate patients.   

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
Tweetorial: Reviewing LAI vs. Oral Data in the Treatment of Schizophrenia

The content for this activity is available here on Twitter

Overview

Experts compare data on hospitalization, adherence, relapse risk, tolerance and efficacy between LAIs and OAs in the treatment of schizophrenia. 

Learning Objectives

After completing this educational activity, you should be able to: 

  • Examine data comparing the efficacy of LAIAs and oral medications.   
  • Analyze the clinical trial data and unique considerations of available LAIAs.   
  • Implement early integration of LAIA therapies in appropriate patients.   

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
 Tweetorial: Parkinson’s Disease Psychosis: Best Practices for Diagnosing PDP

The content for this activity is available here on Twitter

Overview

Parkinson’s disease psychosis (PDP) is a nonmotor symptom of Parkinson’s disease (PD) and includes at least 1 symptom of hallucinations, illusions, delusions, or false sense of presence after onset of PD and recurrent/continuous for 1 month or more. 

Learning Objective

After completing this educational activity, you should be able to: 

  • Identify appropriate best practices for the diagnosis of Parkinson’s disease psychosis 

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation